Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.
Identifieur interne : 001958 ( PubMed/Curation ); précédent : 001957; suivant : 001959Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.
Auteurs : F. Trillsch [Allemagne] ; S. Mahner [Allemagne] ; F. Hilpert [Allemagne] ; L. Davies [Australie] ; E. García-Martínez [Espagne] ; G. Kristensen [Norvège] ; A. Savarese [Italie] ; P. Vuylsteke [Belgique] ; M. Los [Pays-Bas] ; F. Zagouri [Grèce] ; L. Gladieff [France] ; J. Sehouli [Allemagne] ; C. Khoon Lee [Australie] ; V. Gebski [Australie] ; E. Pujade-Lauraine [France]Source :
- Annals of oncology : official journal of the European Society for Medical Oncology [ 1569-8041 ] ; 2016.
Abstract
Progression-free survival (PFS), objective response rate (ORR), and patient-reported outcomes (PROs) were significantly improved by adding bevacizumab to chemotherapy for platinum-resistant ovarian cancer (PROC) in the phase III AURELIA trial. We explored treatment outcomes according to primary platinum resistance (PPR) versus secondary platinum resistance (SPR).
DOI: 10.1093/annonc/mdw236
PubMed: 27287207
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001982
Links to Exploration step
pubmed:27287207Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.</title><author><name sortKey="Trillsch, F" sort="Trillsch, F" uniqKey="Trillsch F" first="F" last="Trillsch">F. Trillsch</name><affiliation wicri:level="3"><nlm:affiliation>Department of Gynecology and Obstetrics, AGO and University of Munich, Munich Department of Gynecology and Gynecologic Oncology, AGO and University Medical Center Hamburg-Eppendorf, Hamburg.</nlm:affiliation><country>Allemagne</country><placeName><settlement type="city">Hambourg</settlement><region type="land" nuts="2">Hambourg</region></placeName><wicri:orgArea>Department of Gynecology and Obstetrics, AGO and University of Munich, Munich Department of Gynecology and Gynecologic Oncology, AGO and University Medical Center Hamburg-Eppendorf</wicri:orgArea></affiliation></author><author><name sortKey="Mahner, S" sort="Mahner, S" uniqKey="Mahner S" first="S" last="Mahner">S. Mahner</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gynecology and Obstetrics, AGO and University of Munich, Munich sven.mahner@med.uni-muenchen.de.</nlm:affiliation><country wicri:rule="url">Allemagne</country><wicri:regionArea>Department of Gynecology and Obstetrics, AGO and University of Munich</wicri:regionArea></affiliation></author><author><name sortKey="Hilpert, F" sort="Hilpert, F" uniqKey="Hilpert F" first="F" last="Hilpert">F. Hilpert</name><affiliation wicri:level="1"><nlm:affiliation>AGO and Onkologisches Therapiezentrum am Krankenhaus Jerusalem, Hamburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>AGO and Onkologisches Therapiezentrum am Krankenhaus Jerusalem, Hamburg</wicri:regionArea></affiliation></author><author><name sortKey="Davies, L" sort="Davies, L" uniqKey="Davies L" first="L" last="Davies">L. Davies</name><affiliation wicri:level="1"><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>NHMRC Clinical Trials Centre, University of Sydney, Camperdown</wicri:regionArea></affiliation></author><author><name sortKey="Garcia Martinez, E" sort="Garcia Martinez, E" uniqKey="Garcia Martinez E" first="E" last="García-Martínez">E. García-Martínez</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Medical Oncology, GEICO and University Hospital JM Morales Meseguer, Murcia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Hematology and Medical Oncology, GEICO and University Hospital JM Morales Meseguer, Murcia</wicri:regionArea></affiliation></author><author><name sortKey="Kristensen, G" sort="Kristensen, G" uniqKey="Kristensen G" first="G" last="Kristensen">G. Kristensen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gynecologic Oncology and Institute for Cancer Genetics and Informatics and Institute for Clinical Medicine, NSGO and Oslo University Hospital, University of Oslo, Oslo, Norway.</nlm:affiliation><country xml:lang="fr">Norvège</country><wicri:regionArea>Department of Gynecologic Oncology and Institute for Cancer Genetics and Informatics and Institute for Clinical Medicine, NSGO and Oslo University Hospital, University of Oslo, Oslo</wicri:regionArea></affiliation></author><author><name sortKey="Savarese, A" sort="Savarese, A" uniqKey="Savarese A" first="A" last="Savarese">A. Savarese</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology '1', MITO and Regina Elena National Cancer Institute, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medical Oncology '1', MITO and Regina Elena National Cancer Institute, Rome</wicri:regionArea></affiliation></author><author><name sortKey="Vuylsteke, P" sort="Vuylsteke, P" uniqKey="Vuylsteke P" first="P" last="Vuylsteke">P. Vuylsteke</name><affiliation wicri:level="1"><nlm:affiliation>Medical Oncology, BGOG and CHU UCL Namur, Site Sainte Elisabeth, Namur, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Medical Oncology, BGOG and CHU UCL Namur, Site Sainte Elisabeth, Namur</wicri:regionArea></affiliation></author><author><name sortKey="Los, M" sort="Los, M" uniqKey="Los M" first="M" last="Los">M. Los</name><affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine/Oncology, DGOG and St Antonius Ziekenhuis, Nieuwegein, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Internal Medicine/Oncology, DGOG and St Antonius Ziekenhuis, Nieuwegein</wicri:regionArea></affiliation></author><author><name sortKey="Zagouri, F" sort="Zagouri, F" uniqKey="Zagouri F" first="F" last="Zagouri">F. Zagouri</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Therapeutics, HECOG and University of Athens, Medical School, Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>Department of Clinical Therapeutics, HECOG and University of Athens, Medical School, Athens</wicri:regionArea></affiliation></author><author><name sortKey="Gladieff, L" sort="Gladieff, L" uniqKey="Gladieff L" first="L" last="Gladieff">L. Gladieff</name><affiliation wicri:level="1"><nlm:affiliation>Institut Claudius-Regaud, Departement d'Oncologie Médicale, GINECO and Centre Hospitalier Universitaire de Toulouse, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut Claudius-Regaud, Departement d'Oncologie Médicale, GINECO and Centre Hospitalier Universitaire de Toulouse, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Sehouli, J" sort="Sehouli, J" uniqKey="Sehouli J" first="J" last="Sehouli">J. Sehouli</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gynecology, AGO and Charité Medical University of Berlin, Campus Virchow Klinikum, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Gynecology, AGO and Charité Medical University of Berlin, Campus Virchow Klinikum, Berlin</wicri:regionArea></affiliation></author><author><name sortKey="Khoon Lee, C" sort="Khoon Lee, C" uniqKey="Khoon Lee C" first="C" last="Khoon Lee">C. Khoon Lee</name><affiliation wicri:level="1"><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>NHMRC Clinical Trials Centre, University of Sydney, Camperdown</wicri:regionArea></affiliation></author><author><name sortKey="Gebski, V" sort="Gebski, V" uniqKey="Gebski V" first="V" last="Gebski">V. Gebski</name><affiliation wicri:level="1"><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>NHMRC Clinical Trials Centre, University of Sydney, Camperdown</wicri:regionArea></affiliation></author><author><name sortKey="Pujade Lauraine, E" sort="Pujade Lauraine, E" uniqKey="Pujade Lauraine E" first="E" last="Pujade-Lauraine">E. Pujade-Lauraine</name><affiliation wicri:level="1"><nlm:affiliation>GINECO and Université Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre, Site Hôtel Dieu, Oncologie, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>GINECO and Université Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre, Site Hôtel Dieu, Oncologie, Paris</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27287207</idno><idno type="pmid">27287207</idno><idno type="doi">10.1093/annonc/mdw236</idno><idno type="wicri:Area/PubMed/Corpus">001982</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001982</idno><idno type="wicri:Area/PubMed/Curation">001958</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001958</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.</title><author><name sortKey="Trillsch, F" sort="Trillsch, F" uniqKey="Trillsch F" first="F" last="Trillsch">F. Trillsch</name><affiliation wicri:level="3"><nlm:affiliation>Department of Gynecology and Obstetrics, AGO and University of Munich, Munich Department of Gynecology and Gynecologic Oncology, AGO and University Medical Center Hamburg-Eppendorf, Hamburg.</nlm:affiliation><country>Allemagne</country><placeName><settlement type="city">Hambourg</settlement><region type="land" nuts="2">Hambourg</region></placeName><wicri:orgArea>Department of Gynecology and Obstetrics, AGO and University of Munich, Munich Department of Gynecology and Gynecologic Oncology, AGO and University Medical Center Hamburg-Eppendorf</wicri:orgArea></affiliation></author><author><name sortKey="Mahner, S" sort="Mahner, S" uniqKey="Mahner S" first="S" last="Mahner">S. Mahner</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gynecology and Obstetrics, AGO and University of Munich, Munich sven.mahner@med.uni-muenchen.de.</nlm:affiliation><country wicri:rule="url">Allemagne</country><wicri:regionArea>Department of Gynecology and Obstetrics, AGO and University of Munich</wicri:regionArea></affiliation></author><author><name sortKey="Hilpert, F" sort="Hilpert, F" uniqKey="Hilpert F" first="F" last="Hilpert">F. Hilpert</name><affiliation wicri:level="1"><nlm:affiliation>AGO and Onkologisches Therapiezentrum am Krankenhaus Jerusalem, Hamburg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>AGO and Onkologisches Therapiezentrum am Krankenhaus Jerusalem, Hamburg</wicri:regionArea></affiliation></author><author><name sortKey="Davies, L" sort="Davies, L" uniqKey="Davies L" first="L" last="Davies">L. Davies</name><affiliation wicri:level="1"><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>NHMRC Clinical Trials Centre, University of Sydney, Camperdown</wicri:regionArea></affiliation></author><author><name sortKey="Garcia Martinez, E" sort="Garcia Martinez, E" uniqKey="Garcia Martinez E" first="E" last="García-Martínez">E. García-Martínez</name><affiliation wicri:level="1"><nlm:affiliation>Department of Hematology and Medical Oncology, GEICO and University Hospital JM Morales Meseguer, Murcia, Spain.</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Department of Hematology and Medical Oncology, GEICO and University Hospital JM Morales Meseguer, Murcia</wicri:regionArea></affiliation></author><author><name sortKey="Kristensen, G" sort="Kristensen, G" uniqKey="Kristensen G" first="G" last="Kristensen">G. Kristensen</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gynecologic Oncology and Institute for Cancer Genetics and Informatics and Institute for Clinical Medicine, NSGO and Oslo University Hospital, University of Oslo, Oslo, Norway.</nlm:affiliation><country xml:lang="fr">Norvège</country><wicri:regionArea>Department of Gynecologic Oncology and Institute for Cancer Genetics and Informatics and Institute for Clinical Medicine, NSGO and Oslo University Hospital, University of Oslo, Oslo</wicri:regionArea></affiliation></author><author><name sortKey="Savarese, A" sort="Savarese, A" uniqKey="Savarese A" first="A" last="Savarese">A. Savarese</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medical Oncology '1', MITO and Regina Elena National Cancer Institute, Rome, Italy.</nlm:affiliation><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Medical Oncology '1', MITO and Regina Elena National Cancer Institute, Rome</wicri:regionArea></affiliation></author><author><name sortKey="Vuylsteke, P" sort="Vuylsteke, P" uniqKey="Vuylsteke P" first="P" last="Vuylsteke">P. Vuylsteke</name><affiliation wicri:level="1"><nlm:affiliation>Medical Oncology, BGOG and CHU UCL Namur, Site Sainte Elisabeth, Namur, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Medical Oncology, BGOG and CHU UCL Namur, Site Sainte Elisabeth, Namur</wicri:regionArea></affiliation></author><author><name sortKey="Los, M" sort="Los, M" uniqKey="Los M" first="M" last="Los">M. Los</name><affiliation wicri:level="1"><nlm:affiliation>Department of Internal Medicine/Oncology, DGOG and St Antonius Ziekenhuis, Nieuwegein, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Internal Medicine/Oncology, DGOG and St Antonius Ziekenhuis, Nieuwegein</wicri:regionArea></affiliation></author><author><name sortKey="Zagouri, F" sort="Zagouri, F" uniqKey="Zagouri F" first="F" last="Zagouri">F. Zagouri</name><affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Therapeutics, HECOG and University of Athens, Medical School, Athens, Greece.</nlm:affiliation><country xml:lang="fr">Grèce</country><wicri:regionArea>Department of Clinical Therapeutics, HECOG and University of Athens, Medical School, Athens</wicri:regionArea></affiliation></author><author><name sortKey="Gladieff, L" sort="Gladieff, L" uniqKey="Gladieff L" first="L" last="Gladieff">L. Gladieff</name><affiliation wicri:level="1"><nlm:affiliation>Institut Claudius-Regaud, Departement d'Oncologie Médicale, GINECO and Centre Hospitalier Universitaire de Toulouse, Toulouse, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institut Claudius-Regaud, Departement d'Oncologie Médicale, GINECO and Centre Hospitalier Universitaire de Toulouse, Toulouse</wicri:regionArea></affiliation></author><author><name sortKey="Sehouli, J" sort="Sehouli, J" uniqKey="Sehouli J" first="J" last="Sehouli">J. Sehouli</name><affiliation wicri:level="1"><nlm:affiliation>Department of Gynecology, AGO and Charité Medical University of Berlin, Campus Virchow Klinikum, Berlin, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Gynecology, AGO and Charité Medical University of Berlin, Campus Virchow Klinikum, Berlin</wicri:regionArea></affiliation></author><author><name sortKey="Khoon Lee, C" sort="Khoon Lee, C" uniqKey="Khoon Lee C" first="C" last="Khoon Lee">C. Khoon Lee</name><affiliation wicri:level="1"><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>NHMRC Clinical Trials Centre, University of Sydney, Camperdown</wicri:regionArea></affiliation></author><author><name sortKey="Gebski, V" sort="Gebski, V" uniqKey="Gebski V" first="V" last="Gebski">V. Gebski</name><affiliation wicri:level="1"><nlm:affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>NHMRC Clinical Trials Centre, University of Sydney, Camperdown</wicri:regionArea></affiliation></author><author><name sortKey="Pujade Lauraine, E" sort="Pujade Lauraine, E" uniqKey="Pujade Lauraine E" first="E" last="Pujade-Lauraine">E. Pujade-Lauraine</name><affiliation wicri:level="1"><nlm:affiliation>GINECO and Université Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre, Site Hôtel Dieu, Oncologie, Paris, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>GINECO and Université Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre, Site Hôtel Dieu, Oncologie, Paris</wicri:regionArea></affiliation></author></analytic><series><title level="j">Annals of oncology : official journal of the European Society for Medical Oncology</title><idno type="eISSN">1569-8041</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Progression-free survival (PFS), objective response rate (ORR), and patient-reported outcomes (PROs) were significantly improved by adding bevacizumab to chemotherapy for platinum-resistant ovarian cancer (PROC) in the phase III AURELIA trial. We explored treatment outcomes according to primary platinum resistance (PPR) versus secondary platinum resistance (SPR).</div></front></TEI><pubmed><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">27287207</PMID><DateCreated><Year>2016</Year><Month>08</Month><Day>27</Day></DateCreated><DateRevised><Year>2016</Year><Month>10</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1569-8041</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>9</Issue><PubDate><Year>2016</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title><ISOAbbreviation>Ann. Oncol.</ISOAbbreviation></Journal><ArticleTitle>Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.</ArticleTitle><Pagination><MedlinePgn>1733-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/annonc/mdw236</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Progression-free survival (PFS), objective response rate (ORR), and patient-reported outcomes (PROs) were significantly improved by adding bevacizumab to chemotherapy for platinum-resistant ovarian cancer (PROC) in the phase III AURELIA trial. We explored treatment outcomes according to primary platinum resistance (PPR) versus secondary platinum resistance (SPR).</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Patients were categorized as PPR (disease progression <6 months after completing first-line platinum therapy) or SPR (progression ≥6 months after first platinum but <6 months after second). The exploratory Cox and logistic regression analyses correlated PFS, ORR, overall survival (OS), and PROs with the time to development of platinum resistance.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Baseline characteristics were similar in patients with PPR (n = 262; 73%) and SPR (n = 99; 27%), although ascites were more common in the PPR subgroup. In bevacizumab-treated patients (n = 179), SPR was associated with improved PFS (median 10.2 versus 5.6 months in PPR patients; P < 0.001) and OS (median 22.2 versus 13.7 months, respectively; P < 0.001) but not PROs (22% versus 22% with improved abdominal/gastrointestinal symptoms at week 8/9). In multivariate analyses, SPR remained an independent prognostic factor for better PFS [adjusted hazard ratio (HR) 0.41, 95% confidence interval (CI) 0.25-0.67; P < 0.001] and OS (HR 0.49, 95% CI 0.30-0.80; P = 0.005) in bevacizumab-treated patients, but was not statistically significant for either end point in the chemotherapy-alone subgroup. The magnitude of PFS benefit from bevacizumab appeared greater in SPR than PPR patients (HR 0.30 versus 0.55, respectively; interaction P = 0.07) with a similar direction of effect for OS (interaction P = 0.18).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In bevacizumab-treated patients, PFS and OS were more favorable in SPR than PPR patients with equally improved PROs. The PFS and OS benefit from combining bevacizumab with chemotherapy was more pronounced in SPR than PPR PROC. PPR versus SPR should be a stratification factor in future trials evaluating anti-angiogenic therapy for PROC.</AbstractText><CopyrightInformation>© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Trillsch</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Gynecology and Obstetrics, AGO and University of Munich, Munich Department of Gynecology and Gynecologic Oncology, AGO and University Medical Center Hamburg-Eppendorf, Hamburg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahner</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Gynecology and Obstetrics, AGO and University of Munich, Munich sven.mahner@med.uni-muenchen.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hilpert</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>AGO and Onkologisches Therapiezentrum am Krankenhaus Jerusalem, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>García-Martínez</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Hematology and Medical Oncology, GEICO and University Hospital JM Morales Meseguer, Murcia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kristensen</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Gynecologic Oncology and Institute for Cancer Genetics and Informatics and Institute for Clinical Medicine, NSGO and Oslo University Hospital, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savarese</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology '1', MITO and Regina Elena National Cancer Institute, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vuylsteke</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Medical Oncology, BGOG and CHU UCL Namur, Site Sainte Elisabeth, Namur, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Los</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine/Oncology, DGOG and St Antonius Ziekenhuis, Nieuwegein, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zagouri</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Clinical Therapeutics, HECOG and University of Athens, Medical School, Athens, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gladieff</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institut Claudius-Regaud, Departement d'Oncologie Médicale, GINECO and Centre Hospitalier Universitaire de Toulouse, Toulouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sehouli</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Gynecology, AGO and Charité Medical University of Berlin, Campus Virchow Klinikum, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khoon Lee</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gebski</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>NHMRC Clinical Trials Centre, University of Sydney, Camperdown, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pujade-Lauraine</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>GINECO and Université Paris Descartes, AP-HP, Hôpitaux Universitaires Paris Centre, Site Hôtel Dieu, Oncologie, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Oncol</MedlineTA><NlmUniqueID>9007735</NlmUniqueID><ISSNLinking>0923-7534</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">anti-angiogenic therapy</Keyword><Keyword MajorTopicYN="N">bevacizumab</Keyword><Keyword MajorTopicYN="N">platinum resistance</Keyword><Keyword MajorTopicYN="N">prognostic factors</Keyword><Keyword MajorTopicYN="N">recurrent ovarian cancer</Keyword><Keyword MajorTopicYN="N">response rates</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>05</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>05</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27287207</ArticleId><ArticleId IdType="pii">mdw236</ArticleId><ArticleId IdType="doi">10.1093/annonc/mdw236</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001958 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001958 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:27287207
|texte= Prognostic and predictive effects of primary versus secondary platinum resistance for bevacizumab treatment for platinum-resistant ovarian cancer in the AURELIA trial.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:27287207" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |